ABK Biomedical Founded

Founded at Dalhousie University in 2012, The Three Founders; Interventional Radiologist Robert Abraham, MD, and Material Scientists, Dr’s Daniel Boyd, and Sharon Kehoe, engineered and patented a new platform technology based on “x-ray visible” glass microspheres.

Manufacturing

Production of proprietary glass microspheres began in Halifax, Nova Scotia.

Delivery System

1st Generation delivery system was developed for bland microspheres.

Focus on Yttrium90 (Y90)

ABK’s proprietary glass microspheres were redesigned with a focus on Y90 radioembolization.

New Management Team

An experienced management team was hired under new CEO and President Mike Mangano.

Raised $30M USD in Series B Funding

The largest medical device venture capital raise in Atlantic Canada is used to further develop Eye90 microspheres®, and Easi-Vue™ embolic microspheres.

Multi-year Strategic Partnership with MURR®

The Missouri University Research Reactor Center is the primary irradiation partner for ABK’s radioembolization products.

Eye90 microspheres®

Finalized design and completed pre-clinical testing for Eye90 microspheres® technology.

Accelerated Manufacturing

Commissioned two new manufacturing and cleanroom facilities to accelerate device operations.

Clinical Transition

ABK Biomedical transitioned from a pre-clinical to a clinical-stage company with the initiation of the First-in-Human clinical study with Eye90 microspheres® in November 2021.

Regulatory Execution

ABK Biomedical announced the first patient treated with Eye90 microspheres® in early 2022 and achieved 510(k) clearance from the FDA for Easi-Vue™ embolic microspheres in September 2022.

FDA IDE Approval

ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma in 2023.

FDA Breakthrough Device Designation

ABK Biomedical Announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by the U.S Food and Drug Administration (FDA).

ISO Certification

ABK Biomedical Achieves Certificate of Registration, Quality Management System – ISO 13485:2016.

ABK Biomedical Recognition

ABK Biomedical Achieves Certificate of Registration, Quality Management System – ISO 13485:2016.

Route90 Stage 2 Approval

ABK Biomedical Announces FDA IDE Approval for Route 90, a Prospective, Multi-center, Pivotal Study of Eye90 microspheres in Unresectable Hepatocellular Cancer (HCC).

$35M USD Series D Capital Funding

ABK Biomedical announces a USD$35M oversubscribed Series D capital raise to help prepare for the commercialization of Eye90 microspheres® and to drive further product innovation and development. 

ROUTE90 Trial Enrollment Completed

On February 24, 2026 ABK Biomedical announces its ROUTE90 pivotal study evaluating Eye90 microspheres in primary liver cancer has completed enrollment. 

ABK Biomedical and MURR Forge Long-Term Partnership to Advance Breakthrough Cancer Therapy

ABK Biomedical and the University of Missouri Research Reactor (MURR) have formalized a long-term agreement naming MURR as the primary irradiation partner for Eye90 microspheres®, an advanced Y-90 radioembolization therapy for liver cancer, building on seven years of existing collaboration.

ABK Biomedical and COR Development Partner to Establish Long-Term Commercial Manufacturing Facility in Ashland, Missouri

ABK Biomedical and COR Development have announce a strategic partnership to build a dedicated GMP manufacturing facility in Cartwright Business Park in Ashland, Missouri, intended to serve as the long-term commercial-scale production site for Eye90 microspheres®, an FDA breakthrough-designated liver cancer therapy.